
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
37.6 (USD) • At close March 11, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Praxis Precision Medicines, Inc. |
Symbool | PRAX |
Munteenheid | USD |
Prijs | 37.6 |
Beurswaarde | 758,140,080 |
Dividendpercentage | 0% |
52-weken bereik | 30.01 - 91.83 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Marcio Souza M.B.A. |
Website | https://www.praxismedicines.com |
An error occurred while fetching data.
Over Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)